HomeAI · summaries
Storia in 2 fonti
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
Confronto fonti
2 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
Eli Lilly blows past estimates, hikes guidance as Zepbound and Mounjaro sales soar
The results come as Eli Lilly works to maintain its edge over Novo Nordisk in the booming market for a class of obesity and diabetes drugs called GLP-1s.
- ·
We're raising our Eli Lilly price target — what a difference a quarter makes
The drugmaker posted a strong third quarter, driven by sales of its popular GLP-1 medications
